CA 125 shedding is not a constitutive and stable process but may be affected by cell cycle and cell proliferation as well as by various growth factors and cytokines. Interferons, interleukin-1β, tumor necrosis factor-α and transforming growth factor-α have been shown to induce while glucocorticoids and transforming growth factor-β have been shown to suppress the release of the tumor marker CA 125 from ovarian carcinoma cells. Several endogenous as well as exogenous factors may affect CA 125 biosynthesis; however, a major question remains whether this observed modulation of CA 125 expression in vitro is of clinical importance.
BastR.C., KlugT.L., St. JohnE.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med1983; 309: 883–7.
2.
FishR.G., ShelleyM.D., MaughanT., RockerI., AdamsM.The clinical value of serum CA 125 levels in ovarian cancer patients receiving platinum therapy.Eur J Cancer Clin Oncol1987; 23: 831–5.
3.
MakarA.P., KristensenG.B., BørmerO.P., TropéC.G.Serum CA 125 level allows early identification of non-responders during induction chemotherapy.Gynecol Oncol1993; 49: 73–9.
4.
RustinG.J.S., NelstropA.E., McCleanP.Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.J Clin Oncol1996; 14: 1545–51.
5.
Van der BurgM.E.L., LammesF.B., Van PuttenW.L.J., StoterG.Ovarian cancer: the prognostic value of the serum half life of CA 125 during induction chemotherapy.Gynecol Oncol1988; 30: 307–12.
6.
BullerR.E., VasilevS., DiSaiaPJ: CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s.Am J Obstet Gynecol1996; 174: 1241–54.
7.
MarkmanM.CA 125: An evolving role in the management of ovarian cancer.J Clin Oncol1996; 14: 1411–12.
8.
MarthC., ZeimetA.G., BöckG., DaxenbichlerG.Modulation of tumor marker CA 125 expression in cultured ovarian carcinoma cells.Eur J Cancer1992; 24A: 2002–6.
9.
MasuhoY., ZalutskyM., KnappR.C., BastR.C.Jr.. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas.Cancer Res1984; 44: 2813–9.
10.
MarthC., FuithL.C., BöckG., DaxenbichlerG., DapuntO.Modulation of ovarian carcinoma tumor marker CA 125 by interferon-γ.Cancer Res1989; 49: 6538–42.
11.
FuithL.C., MarthC., Müller-HolznerE., ZechmannW., DaxenbichlerG.Enhancement of CA 125 expression by interferon-γ in ovarian carcinoma xenografts.J Tumor Marker Oncol1991; 2: 85–9.
12.
MarthC., DaxenbichlerG., FuithL.C., DapuntO.Regulation der CA 125 Tumormarkerexpression und Sekretion durch Interferon-γ beim Ovarialkarzinom. In: KaufmannM., JaraschE.D., BastertG., eds. Klinische Tumorimmunologie in der Gynäkologie.München, Bern, Wien, San Francisco, Zuchschwerdt1989; 3–6.
13.
ZeimetA.G., MarthC., OffnerF.A.Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA 125.Gynecol Oncol1996; 62: 384–9.
14.
ZeillemakerA.M., VerbrughH.A., Hoynck van PapendrechtG.M., LeguitP.CA 125 secretion by peritoneal mesothelial cells.J Clin Pathol1994; 47: 263–5.
15.
MarthC., LangT., KozaA., MayerI., DaxenbichlerG.Transforming growth factor-beta (TGF-ß) and ovarian carcinoma cells: regulation of proliferation and surface antigen expression.Cancer Letters1990; 51: 221–5.
16.
KurachiH., AdachiH., MorishigeK.I.Transforming growth factor-α promotes tumor markers secretion from human ovarian cancers in vitro.Cancer1996; 78: 1049–54.
17.
KarlanB.Y., AminW., CasperS.E., LittlefieldB.A.Hormonal regulation of CA 125 tumor marker expression in human ovarian carcinoma cell, inhibition by glucocorticoid.Cancer Res1988; 48: 3502–5.
18.
GirardM.T., HjaltadottirS., Fejes-TothAn, GuyreP.M.Glucocorticoids enhance the γ-interferon augmentation of human monocyte immunoglobulin G Fc receptor expression.J Immunol1987; 138: 3235–41.
